在达拉斯医疗中心启动TULSA程序后，深刻医疗崛起

2025-09-24 00:58

Shares of Profound Medical (NASDAQ:PROF) traded higher after the company announced that Dallas Medical Center is launching the TULSA procedure, a minimally invasive procedure to treat prostate diseases backed by the company’s TULSA-PRO technology.
The Canadian MedTech said that Texas Prostate, a Dallas-based prostate treatment center, has partnered with Dallas Medical Center to conduct TULSA procedures for males with prostate cancer and benign prostatic hyperplasia.
In January, the U.S. Centers for Medicare and Medicaid Services granted Medicare coverage for TULSA procedures performed at three sites of service, including hospital outpatient settings.
According to Profound (NASDAQ:PROF), the collaboration under which Texas Prostate will exclusively perform TULSA procedures at Dallas Medical's MRI suite will significantly broaden Medicare patient access to the treatment.

More on Profound Medical Corp.